Mid-treatment imaging guides radiation de-escalation in oropharynx cancer

Mid-treatment imaging helped guide de-escalation of radiation for certain patients with oropharynx cancer, according to phase 2 study results presented at Multidisciplinary Head and Neck Cancers Symposium.
Fluorodeoxyglucose (FDG)-PET scans performed prior to and during therapy identified which patients with stage I or stage II p16-positive disease could receive lower doses of radiation in the second half of their treatment course without compromising efficacy, results showed.
De-escalated therapy appeared associated with fewer short-term adverse effects.
“While we are careful to slowly

Mid-treatment imaging helped guide de-escalation of radiation for certain patients with oropharynx cancer, according to phase 2 study results presented at Multidisciplinary Head and Neck Cancers Symposium.
Fluorodeoxyglucose (FDG)-PET scans performed prior to and during therapy identified which patients with stage I or stage II p16-positive disease could receive lower doses of radiation in the second half of their treatment course without compromising efficacy, results showed.
De-escalated therapy appeared associated with fewer short-term adverse effects.
“While we are careful to slowly